|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0015133,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0146224,
umls-concept:C0149925,
umls-concept:C0205390,
umls-concept:C0243077,
umls-concept:C0442027,
umls-concept:C1705294,
umls-concept:C2603343
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2002-9-18
|
|
pubmed:abstractText |
Topotecan (9-dimethylaminomethyl-10-hydroxycampthothecin) is a new topoisomerase I inhibitor with promising efficacy in the treatment of patients with small cell lung carcinoma (SCLC). Combination with a topoisomerase II inhibitor may potentate the therapeutic effect of topotecan, although there has been conflicting preclinical information on the combination. The objectives of this study were to establish the maximum tolerated dose and to determine the efficacy of the sequential combination of intravenous topotecan and oral etoposide in the treatment of patients with SCLC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:ChakKarenK,
pubmed-author:ChanAnthony T CAT,
pubmed-author:JohnsonPhilipP,
pubmed-author:LeeTak WaiTW,
pubmed-author:LeungThomas W TTW,
pubmed-author:MokTony S KTS,
pubmed-author:WongHermanH,
pubmed-author:YeoWinnieW,
pubmed-author:YimAnthonyA,
pubmed-author:YuKwok HungKH,
pubmed-author:ZeeBennyB
|
|
pubmed:copyrightInfo |
Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10836
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1511-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12237920-Administration, Oral,
pubmed-meshheading:12237920-Adult,
pubmed-meshheading:12237920-Aged,
pubmed-meshheading:12237920-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12237920-Carcinoma, Small Cell,
pubmed-meshheading:12237920-Dose-Response Relationship, Drug,
pubmed-meshheading:12237920-Drug Administration Schedule,
pubmed-meshheading:12237920-Etoposide,
pubmed-meshheading:12237920-Female,
pubmed-meshheading:12237920-Humans,
pubmed-meshheading:12237920-Infusions, Intravenous,
pubmed-meshheading:12237920-Lung Neoplasms,
pubmed-meshheading:12237920-Male,
pubmed-meshheading:12237920-Middle Aged,
pubmed-meshheading:12237920-Neutropenia,
pubmed-meshheading:12237920-Topotecan
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
|
|
pubmed:affiliation |
Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China. mok206551@cuhk.edu.hk
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
